Missouri is currently home to 1899 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
NCT04354064
Recruiting
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
Register for Updates
Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer
NCT06559540
Recruiting
In breast cancer patients with nodal involvement, numerous studies have demonstrated that adjuvant radiation therapy reduces the risk of local recurrence, regional recurrence, and distant metastases, in addition to improving survival. The dose and fractionation for adjuvant breast radiation therapy has evolved over time, as novel schedules have been compared to the current standard of care. Hypofractionated radiation therapy (266 cGy per fraction x 15-16 fractions over 3 weeks) has been shown to... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Node-positive Breast Cancer
Register for Updates
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
NCT04523727
Recruiting
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
Gender:
ALL
Ages:
Between 6 years and 16 years
Trial Updated:
04/15/2025
Locations: Children's Mercy Hospital - Kansas City, Kansas City, Missouri
Conditions: Hyperphosphatemia Related to Chronic Kidney Disease
Register for Updates
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
NCT01351545
Recruiting
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Gender:
ALL
Ages:
All
Trial Updated:
04/15/2025
Locations: Children's Mercy Hospital and Clinics, Kansas City, Missouri
Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Severe Aplastic Anemia, Autoimmune Diseases
Register for Updates
PREVENT ALL ALS Study
NCT06581861
Recruiting
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is begin funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The cl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Washington University, Saint Louis, Missouri
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
NCT06253130
Recruiting
This study will evaluate the preliminary efficacy of IMP1734 in patients with recurrent advanced/metastatic breast cancer, ovarian cancer and metastatic castrate resistant prostate cancer (mCRPC) with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/14/2025
Locations: Washington University - Siteman Cancer Center, Saint Louis, Missouri
Conditions: Advanced Solid Tumor
Register for Updates
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297
Recruiting
The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonstrating its clinical benefit and increasing levels of circulating neutrophils.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/14/2025
Locations: Washington University, Saint Louis, Missouri
Conditions: Neutropenia
Register for Updates
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
NCT05346354
Recruiting
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).
Gender:
ALL
Ages:
All
Trial Updated:
04/14/2025
Locations: Research Site, Saint Louis, Missouri
Conditions: Neuromyelitis Optica Spectrum Disorder
Register for Updates
Trifecta-Kidney cfDNA-MMDx Study
NCT04239703
Recruiting
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.
Gender:
ALL
Ages:
All
Trial Updated:
04/14/2025
Locations: Barnes-Jewish Hospital, Washington University at St. Louis, Saint Louis, Missouri
Conditions: Kidney Transplant Rejection
Register for Updates
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
NCT00904241
Recruiting
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/14/2025
Locations: Columbia Regional, Columbia, Missouri
Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Register for Updates
Group CBT in Parents of Children With Food Allergy
NCT06138431
Recruiting
Parents of children with food allergies that are medically established will be able to participate in 6 one-hour weekly virtual Cognitive Behavioral Therapy (CBT) groups, and outcomes will be measured for anxiety, depression and quality of life. Possible benefits include improvement in psychological functioning and quality of life of families, as well as improved understanding of the use of group Cognitive Behavioral Therapy (CBT) for parents of children with medically established food allergies... Read More
Gender:
ALL
Ages:
Between 18 months and 17 years
Trial Updated:
04/13/2025
Locations: University Health Behavioral Health Canvas Building, Kansas City, Missouri
Conditions: Parents
Register for Updates
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NCT06414954
Recruiting
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2025
Locations: NextGen Precision Health, Columbia, Missouri
Conditions: Myasthenia Gravis, Myasthenia Gravis, MuSK
Register for Updates